Medical tourism has a conflict-of-interest problem. Can independent medical review fix it?

Cross-border healthcare can give patients greater choice, access and potentially substantial savings. But when medical advice and the business of arranging treatment are financially connected, an uncomfortable question arises: Who gets paid for telling the patient not to travel?

Imagine a patient has been told that she needs surgery.

The procedure is expensive in her home country, so she begins exploring treatment overseas. She contacts a medical-tourism intermediary, uploads her records and receives recommendations for hospitals and specialists abroad.

The options look compelling. The hospitals are modern. The physicians appear highly qualified. The treatment prices are substantially lower.

There is just one question that may never get asked:

Does she need to travel for treatment at all?

Perhaps the original diagnosis should first be independently confirmed.

Perhaps another treatment option exists.

Perhaps additional diagnostic testing is needed.

Perhaps the surgery is appropriate, but it can be performed effectively near her home.

Or perhaps international treatment genuinely offers an important advantage in expertise, access or cost.

Any of those conclusions could be medically reasonable.

But they may not be economically equivalent for everyone involved in the transaction.

That is the conflict-of-interest problem medical tourism needs to confront.

It is not necessarily a story about misconduct.

It is a story about incentive design.

Follow the incentives

Most industries employ intermediaries.

Travel agents help travelers book hotels and flights. Real-estate brokers connect buyers and sellers. Insurance brokers help customers select coverage.

The intermediary typically earns money when a transaction occurs.

That model becomes more complicated in healthcare because the customer is not merely asking:

Where should I buy this?

The patient may also be asking:

Should I buy this at all?

Those are fundamentally different questions.

Consider a medical-tourism facilitator whose business model depends on referral fees, commissions, service charges or other revenue connected to a patient ultimately receiving treatment.

There is nothing inherently improper about being paid for arranging a service.

Hospitals need patients. Facilitators perform real work. International cases can involve medical-record coordination, appointments, visas, accommodation, transportation, interpreters and complex logistics.

The problem arises when the same commercial pathway also influences the answer to the patient's underlying clinical question.

If revenue occurs primarily when the patient travels or undergoes treatment, what happens when the medically appropriate recommendation is:

"Don't travel."

Who gets paid for that outcome?

That question deserves far more attention as cross-border healthcare expands.

Conflicts of interest are structural, not necessarily ethical failures

Healthcare already recognizes conflicts of interest in many forms.

Physician relationships with pharmaceutical companies are disclosed. Researchers report financial relationships. Medical journals require authors to declare competing interests. Hospitals create rules around procurement and referrals.

The reason is not that every financial relationship causes improper behavior.

It is that incentives can influence judgment—or create the perception that judgment has been influenced.

The same principle should apply to medical tourism.

A physician employed by a hospital may sincerely believe that the hospital offers the patient's best treatment option.

A facilitator receiving a referral payment may genuinely believe that the recommended provider is appropriate.

A patient coordinator may be acting entirely in good faith.

Yet from the patient's perspective, an important uncertainty remains:

Would I receive the same recommendation if no one earned money from my treatment?

That perception alone matters.

Patients making major medical decisions are being asked to trust not only the competence of the people advising them, but also the architecture surrounding that advice.

Good systems should not depend entirely on good intentions.

They should make trustworthy behavior easier to demonstrate.

Separate medical advice from travel conversion

There is a relatively simple principle that could improve this system:

Separate medical advice from travel conversion.

Before deciding where to travel, a patient considering international treatment could receive an independent review of the diagnosis, medical records and proposed treatment.

The reviewing specialist would be compensated for providing medical judgment.

Not for generating a hospital admission.

Not for selling a procedure.

Not for booking a flight.

And not for converting the patient into a medical traveler.

The physician would receive the same professional fee whether the recommendation is:

Don't travel.

Complete additional diagnostics first.

Consider international treatment.

This does not eliminate every conflict of interest in healthcare.

Nothing does.

But it changes an important incentive.

The person answering "What should I do medically?" no longer needs the answer to be "Travel for treatment" in order to be compensated.

The second opinion should come before the destination

This also suggests that medical tourism may often begin at the wrong point in the patient's journey.

A conventional process might look like this:

Patient searches destination → contacts facilitator → selects hospital → hospital reviews records → treatment is proposed → patient travels.

A decision-first model would reverse part of that sequence:

Patient submits records → independent specialist reviews case → patient understands options → travel decision is made → destinations and providers are evaluated.

That difference is significant.

In the first model, the patient enters a system designed to facilitate international treatment.

In the second, the patient enters a system designed first to determine whether international treatment makes sense.

The destination comes later.

This idea is consistent with existing public-health guidance. The U.S. Centers for Disease Control and Prevention recommends that people considering medical tourism discuss their plans with a healthcare professional well before travel. CDC guidance also emphasizes researching clinicians and facilities, understanding potential complications and arranging follow-up care. CDC guidance on medical tourism

In other words, medical travel should begin with medical judgment—not travel planning.

Three answers should be equally acceptable

A genuinely independent review system must be comfortable producing three different outcomes.

The first is:

You don't need to travel.

Perhaps appropriate treatment is readily available locally.

Perhaps the international option offers no meaningful clinical advantage once travel, recovery and follow-up are considered.

From a travel-conversion perspective, that patient has been lost.

From a healthcare perspective, the system may have worked perfectly.

The second outcome is:

We don't know enough yet.

A pathology review may be required.

Another scan may be necessary.

The diagnosis may need confirmation.

Additional laboratory testing may materially change the treatment recommendation.

In medicine, delaying a decision until adequate information exists can be better than confidently making the wrong decision.

The third outcome is:

International treatment is worth considering.

Perhaps another country offers expertise unavailable locally.

Perhaps treatment can be obtained substantially sooner.

Perhaps the economics are compelling.

Perhaps the patient has family or cultural connections to the destination.

At this point, the patient can begin evaluating hospitals, physicians, accreditation, treatment costs and travel arrangements.

All three outcomes should count as successful medical reviews.

That principle sounds simple.

Economically, it is surprisingly disruptive.

Medical tourism should borrow an idea from financial advice

There is a useful analogy in another highly regulated industry.

Financial services has spent decades debating the difference between selling a financial product and providing advice in the client's best interest.

The two activities can coexist.

But consumers need to understand which one they are receiving.

Healthcare deserves at least as much clarity.

A patient contacting an international hospital may understand that the hospital wants to provide treatment.

A patient contacting a travel facilitator may understand that the facilitator makes money arranging travel and care.

But an independent medical reviewer should occupy a different position.

The reviewer is not selling the destination.

The reviewer is selling professional judgment.

That distinction could become one of the foundations of trust in cross-border healthcare.

Disclosure is necessary—but it may not be sufficient

The obvious response to conflicts of interest is disclosure.

A facilitator could tell patients:

"We may receive compensation from hospitals when patients receive treatment."

That transparency is useful.

But disclosure alone does not change the underlying economic structure.

A stronger approach is to redesign the incentive itself.

If the clinician conducting the initial review receives a fixed fee regardless of what the patient subsequently chooses, the compensation structure no longer rewards a particular recommendation.

The patient's subsequent commercial journey can then be separated from the clinical assessment.

This is particularly important for serious conditions where treatment decisions may be consequential, expensive and difficult to reverse.

Patients should be able to distinguish between:

medical advice,

provider recommendation,

and

travel facilitation.

Those activities can exist within the same broader ecosystem.

They should not be confused with one another.

A radical transparency metric: the "don't-travel rate"

There is another way the industry could demonstrate independence.

Medical-tourism companies typically highlight the number of patients treated, hospitals in their networks, procedures arranged, countries served and potential savings.

Consider publishing a different metric:

The percentage of prospective medical travelers advised not to travel.

Call it the don't-travel rate.

At first, this seems like a strange business metric.

Imagine an airline advertising how many people it persuaded not to fly.

But healthcare is different.

If an organization claims to put clinical appropriateness ahead of travel conversion, then some patients should logically be told that international treatment is unnecessary.

Publishing that proportion would provide evidence that "don't travel" is not merely a theoretical option.

The metric would need careful definitions.

A patient might be advised not to travel because treatment is available locally.

Another might be medically unfit for travel.

Another might need further diagnostic testing.

Another might discover that the expected benefit of the proposed treatment does not justify its risks.

And some patients initially advised not to travel may later become appropriate candidates after their circumstances change.

The number therefore should not become a simplistic league table in which a higher rate automatically means greater integrity.

Its value is transparency.

It demonstrates that the pathway contains an actual off-ramp.

Transparency could change competition

Imagine two medical-tourism platforms.

Platform A reports:

12,000 patients facilitated.

100 hospitals.

30 countries.

Savings up to 70%.

Platform B reports those conventional measures but adds:

1,000 independent medical reviews completed.

18% advised to seek additional diagnostics before making a travel decision.

14% advised that international travel was not currently necessary.

Which platform would a worried patient trust more?

Potentially, the company that can demonstrate that it sometimes chooses not to make the sale.

This could create a healthier form of competition.

Instead of competing only on hospital inventory, procedure prices and convenience, platforms could compete on independence, transparency and outcomes.

Provider recommendation creates another conflict

Separating the initial medical review solves only part of the problem.

Suppose the independent specialist concludes that international treatment is reasonable.

The patient then asks:

Which hospital should I choose?

Another potential conflict emerges.

If a facilitator receives different compensation from different hospitals, provider recommendations may be financially influenced—or appear to be.

Again, the solution is not necessarily to prohibit commercial relationships.

It is to make them transparent and design safeguards around them.

Patients should know whether recommended hospitals pay referral or marketing fees.

Provider ranking criteria should be explainable.

Accreditation, physician qualifications, procedure-specific experience, outcomes where available, cost, communication and continuity arrangements should matter more than commercial terms.

The goal should be to make the recommendation defensible even if the financial relationship were displayed next to it.

Price creates yet another incentive

Medical tourism is frequently marketed through dramatic price comparisons.

A procedure costing tens of thousands of dollars in the United States may be advertised abroad for a fraction of the price.

Such differences can be genuine and important.

But price itself can distort decision-making.

A low package price may not include diagnostic tests, implants, additional hospital days, medications, rehabilitation or treatment of complications.

Patients need to understand the total episode-of-care cost, not merely the procedure price.

More importantly, cost should come after clinical appropriateness.

A treatment that costs 70% less is not a bargain if the patient did not need it.

Independent review becomes more important as medical tourism grows

The issue is becoming more consequential because cross-border healthcare is expanding.

Countries including India are actively investing in medical-value travel and seeking substantially larger international patient volumes. India's government has emphasized verified and accredited hospitals, transparent treatment packages, professional integrity, teleconsultation and a more seamless patient journey as it seeks to expand the sector.

That creates an enormous opportunity.

International healthcare can connect patients to specialized expertise, expand choice and make some treatments financially accessible to people who might otherwise struggle to afford them.

But scale magnifies incentive problems.

A system serving tens of thousands of patients can rely heavily on individual relationships.

A system serving millions needs architecture.

Independent medical review can become part of that architecture.

What independence should look like

A credible second-opinion-first system could follow several basic principles.

The reviewing specialist receives a fixed professional fee for reviewing the case.

That fee does not change depending on the recommendation.

The reviewer receives no additional compensation if the patient travels.

The reviewer does not receive a commission if the patient chooses a particular hospital.

The patient is clearly told what role the reviewer is performing.

Commercial relationships involving subsequent treatment or facilitation are separately disclosed.

And aggregate outcomes of independent reviews—including recommendations against travel—are periodically published.

Those principles will not make every medical decision correct.

They can, however, make the incentives easier to understand.

Putting the model into practice

This is the model we are attempting to build at Healing Tourist, a medical second-opinion and treatment-facilitation platform.

A specialist reviewing a patient's case receives a fixed fee for the medical review. The compensation does not increase if the specialist recommends international treatment. The specialist does not participate financially in the patient's subsequent travel booking.

The intended outcomes include all three possibilities:

Stay home.

Get more information.

Consider traveling.

Healing Tourist also plans to publish, on a periodic basis, the proportion of reviewed cases in which specialists advise patients that international travel is unnecessary.

That approach should itself be subject to scrutiny.

The value of a new model is not that its creators say it is independent. Independence should eventually be demonstrated through transparent policies, disclosed relationships and measurable outcomes.

That standard should apply to us as much as anyone else.

The ultimate test: Can the system say no?

There is a simple way to evaluate almost any healthcare marketplace.

Ask what happens when the best decision for the patient produces no transaction.

If a patient does not need surgery, can the system comfortably say so?

If additional diagnostics are necessary, can the transaction stop?

If treatment is available locally, can an international facilitator recommend staying home?

If one hospital is clinically more appropriate but commercially less valuable to the intermediary, which hospital gets recommended?

These questions are uncomfortable precisely because they expose the difference between healthcare and ordinary commerce.

In most markets, converting the customer is the objective.

In healthcare, sometimes the best outcome is not converting the patient at all.

That is why medical tourism's next innovation may not be a new hospital marketplace, an artificial-intelligence recommendation engine or a better travel-booking experience.

It may be something much simpler:

an independent person who gets paid the same amount regardless of whether the answer is yes or no.

As healthcare becomes increasingly global, patients will need more than access to cheaper procedures and famous specialists.

They will need confidence that the advice they receive is designed to help them make the right medical decision—even when that decision produces no flight, no hospital admission and no sale.

For the medical-tourism industry, that may become the most important measure of trust:

Can the system make money telling a patient not to spend money?